Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.04).

GUIDANCE

With the extension of the $100.0 million note, we updated our cash guidance such that we now have sufficient cash to operate into the first quarter of 2025. Our prior cash guidance was to have sufficient funds going into September 2024.

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.